Related Experiment Video
Updated: Jun 5, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Management of atrial fibrillation, what to know on old and new antiarrhythmics]
1Hôpital Européen Georges Pompidou Cardiologie et Rythmologie, Paris XV, France. jean-yves.le-heuzey@egp.aphp.fr
Abstract:
The management of atrial fibrillation, despite the development of ablative techniques, is mainly a pharmacological issue. For the last 25 years, no new oral antiarrhythmic drug has been launched in France. Class I antiarrhythmic drugs are efficient and safe if they are prescribed taking into account their contra-indications, but their therapeutic index is narrow. Class III antiarrhythmic drugs have limits, mainly due to the repolarization prolongation they induce and the risk of torsades de pointes. The mode of action of new antiarrhythmic drugs are based on an IKur blocking approach or on a multichannel blockade approach like that of dronedarone which is the only antiarrhythmic drug, to date, to have demonstrated an interest in terms of morbi-mortality in atrial fibrillation.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

